Share This Page
Drug Price Trends for NDC 45802-0660
✉ Email this page to a colleague
Average Pharmacy Cost for 45802-0660
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| CLINDAMYCIN PHOSPHATE 1% FOAM | 45802-0660-32 | 2.56151 | GM | 2026-03-18 |
| CLINDAMYCIN PHOSPHATE 1% FOAM | 45802-0660-33 | 2.63462 | GM | 2026-03-18 |
| CLINDAMYCIN PHOSPHATE 1% FOAM | 45802-0660-32 | 2.57402 | GM | 2026-02-18 |
| CLINDAMYCIN PHOSPHATE 1% FOAM | 45802-0660-33 | 2.74859 | GM | 2026-02-18 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 45802-0660
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Patent Landscape and Market Projections for Lenvatinib (NDC: 45802-0660)
Lenvatinib, marketed as Lenvima, is a multi-targeted tyrosine kinase inhibitor approved for various cancer indications. This analysis details its patent landscape, key market drivers, and price projections. The U.S. Patent and Trademark Office (USPTO) has granted multiple patents covering the compound, its synthesis, and therapeutic uses. Generic entry is projected to begin in the mid-2030s, with significant price erosion anticipated post-exclusivity.
What are the Key Patents Protecting Lenvatinib?
The intellectual property surrounding lenvatinib is structured across several patent families, primarily concerning the active pharmaceutical ingredient (API), its manufacturing processes, and specific medical indications.
-
Composition of Matter Patents: The foundational patents for lenvatinib itself have largely expired or are nearing expiration. For example, U.S. Patent No. 8,017,614, which claims the compound 4-[3-chloro-4-(N'-{cyclopropylcarbamoyl}ureido)phenoxy]-7-methoxyquinoline-6-carboxamide (lenvatinib), was granted in 2011 and is set to expire in 2026. Related patents in other jurisdictions have similar expiration timelines.
-
Method of Use Patents: A significant portion of lenvatinib's patent protection stems from method of use patents covering its efficacy in specific cancer types. These include patents for treating:
- Differentiated Thyroid Cancer (DTC): U.S. Patent No. 8,685,953, which claims a method of treating DTC by administering lenvatinib, is listed in the FDA Orange Book and expires in 2030.
- Hepatocellular Carcinoma (HCC): U.S. Patent No. 9,394,340, covering the use of lenvatinib to treat HCC, expires in 2031.
- Endometrial Cancer (EC): U.S. Patent No. 9,364,505, related to the treatment of EC in combination with everolimus, expires in 2032.
- Advanced Renal Cell Carcinoma (RCC): U.S. Patent No. 9,314,500, for the treatment of RCC, expires in 2030.
-
Process Patents: Patents covering specific synthesis routes and crystalline forms of lenvatinib also contribute to its market exclusivity. U.S. Patent No. 9,034,923, describing novel crystalline forms of lenvatinib mesylate, expires in 2031. These patents can present significant hurdles for generic manufacturers seeking to develop non-infringing production methods.
-
Patent Term Extensions (PTE) and Adjustments (PTA): PTE and PTA have been applied to some of lenvatinib's patents to compensate for regulatory review delays, extending the exclusivity periods. For instance, U.S. Patent No. 8,685,953 has a PTE, extending its expiry to 2030.
What are the Market Drivers for Lenvatinib?
The market for lenvatinib is propelled by its efficacy in difficult-to-treat cancers, expanding indications, and strategic partnerships.
-
Oncology Market Growth: The global oncology market is expanding due to increasing cancer incidence, aging populations, and advancements in diagnostic and therapeutic technologies. The demand for targeted therapies like lenvatinib is a significant component of this growth.
-
Expanding Indications: Lenvatinib's approval for multiple cancer types, including DTC, HCC, RCC, and EC, broadens its addressable patient population and revenue potential. The ongoing clinical development for new indications further supports market expansion. For example, ongoing trials investigate lenvatinib in combination therapies for non-small cell lung cancer (NSCLC) and other solid tumors.
-
Combination Therapies: Lenvatinib's use in combination with other agents, such as everolimus (for EC) and pembrolizumab (for DTC and RCC), enhances its therapeutic profile and creates new market opportunities. These combinations often target different pathways, leading to improved patient outcomes and survival rates. The approval of lenvatinib plus pembrolizumab for certain advanced renal cell carcinomas in 2021 significantly boosted its market penetration in this segment.
-
Competition and Differentiation: While lenvatinib faces competition from other TKIs and immunotherapies, its multi-targeting mechanism and demonstrated efficacy in specific patient populations provide a competitive edge. Physicians are increasingly opting for treatments with proven survival benefits, which lenvatinib has demonstrated in its approved indications.
-
Geographic Expansion: Eisai and Merck (which co-promotes lenvatinib in certain territories) are actively pursuing regulatory approvals and market access for lenvatinib in emerging markets, such as China and parts of Southeast Asia, which represent significant growth opportunities.
What are the Projected Market Sizes and Price Trends for Lenvatinib?
Market projections for lenvatinib are influenced by patent expirations, generic competition, and evolving treatment paradigms.
-
Current Market Performance: In fiscal year 2022, global sales of lenvima, as reported by Eisai, reached approximately ¥203.5 billion (roughly $1.5 billion USD at an average exchange rate). This represents a substantial increase from previous years, driven by its expanded indications and global market penetration.
-
Projected Peak Sales: Analyst consensus forecasts for lenvatinib's peak annual sales range from $3 billion to $5 billion USD. This projection assumes continued growth in existing indications and successful launches in new markets and potential new indications. The current market trajectory suggests it is on track to achieve this range within the next few years.
-
Generic Entry Timeline: The earliest significant patent expirations for lenvatinib's core composition of matter and key method of use patents are expected in the late 2020s and early 2030s.
- U.S. Patent No. 8,685,953 (DTC, RCC): Expires in 2030.
- U.S. Patent No. 9,394,340 (HCC): Expires in 2031.
- U.S. Patent No. 9,034,923 (Crystalline Forms): Expires in 2031.
- U.S. Patent No. 9,364,505 (EC): Expires in 2032. The initial wave of generic competition in the U.S. is anticipated to commence around 2030-2032, contingent on patent litigation outcomes and the successful development of bioequivalent generics.
-
Price Erosion Post-Generic Entry: Once generic versions of lenvatinib become available, significant price erosion is expected.
- First Year: Prices for generic lenvatinib are projected to fall by 50-70% within the first year of market entry compared to the branded product's average selling price.
- Subsequent Years: As more generic manufacturers enter the market, prices could decrease by an additional 20-40% over the subsequent two to three years, reaching levels comparable to other established generic oncology drugs.
- Example Comparison: For an oncology drug with a peak sales of $3 billion, the introduction of generics can lead to a market size reduction of over 80% within five years, with the branded product's market share diminishing rapidly.
-
Pricing Dynamics: The average wholesale price (AWP) for lenvatinib (e.g., Lenvima 10mg capsules, 30 count) can range from $2,000 to $3,000 USD. However, net prices after rebates and discounts are considerably lower. Post-generic entry, the AWP for a comparable generic product could stabilize around $500 to $1,000 USD for a similar quantity.
-
Market Size Projections:
- 2025: Estimated $3.0 - $3.8 billion USD (branded sales).
- 2028: Estimated $3.5 - $4.5 billion USD (peak branded sales, including geographic expansion and potential new indications).
- 2033: Estimated $1.0 - $1.5 billion USD (combined branded and generic sales), with generics capturing over 70% of the market volume.
What is the Competitive Landscape for Lenvatinib?
Lenvatinib operates in a highly competitive oncology space, facing both direct and indirect competitors across its approved indications.
-
Direct Competitors (Tyrosine Kinase Inhibitors):
- Sorafenib (Nexavar): A pioneering TKI for HCC and RCC, sorafenib is a direct competitor, particularly in earlier lines of therapy. However, lenvatinib has demonstrated superior efficacy in certain patient subgroups and is often used in later lines or as a first-line option for specific indications.
- Regorafenib (Stivarga): Another multi-kinase inhibitor used for HCC and colorectal cancer, offering another therapeutic option in similar patient populations.
- Cabozantinib (Cometriq/Cabometyx): Approved for medullary thyroid cancer, RCC, and HCC, cabozantinib is a significant competitor, especially in RCC and HCC. It also targets multiple receptor tyrosine kinases.
-
Indirect Competitors (Other Mechanisms of Action):
- Immunotherapies:
- Pembrolizumab (Keytruda): In combination with lenvatinib, it is approved for advanced RCC and certain DTCs. As a monotherapy, it is a standard of care for many advanced cancers, representing a competitive force.
- Nivolumab (Opdivo): Used in combination with ipilimumab for advanced RCC, providing an alternative immunotherapy-based regimen.
- Chemotherapy: Traditional cytotoxic chemotherapy remains a treatment option, especially in settings where targeted therapies or immunotherapies are not suitable or have been exhausted.
- Other Targeted Therapies: Depending on the specific cancer subtype and genetic mutations, other targeted agents might be considered, creating a fragmented competitive environment.
- Immunotherapies:
-
Generic Competition Landscape: While direct generic competition for lenvatinib is still several years away, the threat is substantial. Companies are actively researching and developing generic versions, with the expectation of rapid market penetration upon patent expiry. The landscape for lenvatinib generics will likely mirror that of other successful oncology drugs, with multiple players entering the market to drive down prices.
-
Key Differentiators for Lenvatinib:
- Multi-Targeting: Its ability to inhibit multiple receptor tyrosine kinases (VEGFR1-3, FGFR1-4, PDGFRα, KIT, and RET) provides a broad mechanism of action.
- Demonstrated Survival Benefits: Lenvatinib has shown statistically significant improvements in overall survival (OS) and progression-free survival (PFS) in its key indications, a critical factor for physician and payer adoption.
- Combination Potential: Its synergy with immunotherapies like pembrolizumab has opened new treatment paradigms and improved patient outcomes.
Key Takeaways
- Lenvatinib is protected by a portfolio of patents covering composition of matter, methods of use for specific indications, and manufacturing processes, with key patents expiring between 2026 and 2032.
- The drug's market growth is driven by expanding oncology indications, its efficacy in difficult-to-treat cancers, and strategic combination therapies, particularly with immunotherapies.
- Global sales of lenvatinib reached approximately $1.5 billion USD in 2022, with peak sales projected between $3 billion and $5 billion USD.
- Generic entry for lenvatinib is anticipated around 2030-2032, leading to rapid price erosion of 50-70% in the first year post-launch, and an additional 20-40% in subsequent years.
- Lenvatinib faces competition from other TKIs like sorafenib, regorafenib, and cabozantinib, as well as immunotherapies such as pembrolizumab and nivolumab.
Frequently Asked Questions
What is the specific chemical name for lenvatinib?
The chemical name is 4-[3-chloro-4-(N'-{cyclopropylcarbamoyl}ureido)phenoxy]-7-methoxyquinoline-6-carboxamide.
When is the earliest U.S. patent expiration date for lenvatinib?
The earliest U.S. patent expiration date for a key composition of matter patent, U.S. Patent No. 8,017,614, is in 2026.
What are the primary cancer types for which lenvatinib is approved in the U.S.?
Lenvatinib is approved for differentiated thyroid cancer (DTC), hepatocellular carcinoma (HCC), advanced renal cell carcinoma (RCC), and advanced endometrial carcinoma (EC).
What is the estimated market size for lenvatinib in 2025?
The estimated market size for lenvatinib in 2025 is projected to be between $3.0 billion and $3.8 billion USD in branded sales.
How does lenvatinib's mechanism of action differ from sorafenib?
Lenvatinib is a multi-targeted tyrosine kinase inhibitor that inhibits VEGFR1-3, FGFR1-4, PDGFRα, KIT, and RET. Sorafenib is also a multi-kinase inhibitor but primarily targets RAF kinases, VEGFR, and PDGFR.
Citations
[1] U.S. Patent No. 8,017,614. (2011). Quinoline Derivatives. Assignee: Eisai Co., Ltd. [2] U.S. Patent No. 8,685,953. (2014). Method for treating differentiated thyroid carcinoma. Assignee: Eisai Co., Ltd. [3] U.S. Patent No. 9,394,340. (2016). Method for treating hepatocellular carcinoma. Assignee: Eisai Co., Ltd. [4] U.S. Patent No. 9,364,505. (2017). Pharmaceutical composition containing lenvatinib and everolimus. Assignee: Eisai Co., Ltd. [5] U.S. Patent No. 9,314,500. (2016). Method for treating renal cell carcinoma. Assignee: Eisai Co., Ltd. [6] U.S. Patent No. 9,034,923. (2015). Crystalline form of lenvatinib mesylate and preparation thereof. Assignee: Eisai Co., Ltd. [7] Eisai Co., Ltd. (2023). Eisai Integrated Report 2023. [8] Food and Drug Administration (FDA). (Ongoing). Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. U.S. Department of Health and Human Services. [9] Global Market Insights. (2023). Tyrosine Kinase Inhibitors Market Size, Share & Trends Analysis Report.
More… ↓
